During the past decade, Centre Henri Becquerel; Hematologie conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 7 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 2 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Henri Becquerel; Hematologie" #1 sponsor was "Hoffmann-La Roche" with 11 trials, followed by "French Innovative Leukemia Organisation" with 6 trials sponsored, "Genentech, Inc." with 3 trials sponsored, "Groupe Francophone des Myelodysplasies" with 2 trials sponsored and "Celgene" with 2 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Henri Becquerel; Hematologie" #1 collaborator was "AbbVie" with 3 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "Astex Pharmaceuticals, Inc." with 1 trials as a collaborator, "Biogen" with 1 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Centre Henri Becquerel; Hematologie" are "Chronic Lymphocytic Leukemia" (3 trials), "Diffuse Large B-Cell Lymphoma" (3 trials), "Lymphoma" (2 trials), "Lymphoma, Non-Hodgkin" (2 trials) and "AML" (1 trials). Many other conditions were trialed in "Centre Henri Becquerel; Hematologie" in a lesser frequency.

Most popular intervention types in "Centre Henri Becquerel; Hematologie" are "Drug" (23 trials), "Behavioral" (1 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (12 trials), "Cyclophosphamide" (7 trials), "Obinutuzumab" (6 trials), "Doxorubicin" (5 trials) and "Polatuzumab Vedotin" (5 trials). Other intervention names were less common.

The vast majority of trials in "Centre Henri Becquerel; Hematologie" are 24 trials for "All" genders.

Currently, there are NaN active trials in "Centre Henri Becquerel; Hematologie". undefined are not yet recruiting, 8 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Centre Henri Becquerel; Hematologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centre Henri Becquerel; Hematologie, 6 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".